Targeting heart failure with preserved ejection fraction: current status and future prospects

Manreet Kanwar  
Claire Walter  
Megan Clarke  
Maria Patarroyo-Aponte  
Department of Cardiology, Allegheny General Hospital, Pittsburgh, PA, USA

Abstract: Heart failure with preserved ejection fraction (HFpEF) portrays a significant burden in terms of prevalence, morbidity, mortality, and health care costs. There is a lack of consensus on the basic pathophysiology, definition, and therapeutic targets for therapy for this syndrome. To date, there are no approved therapies available for reducing mortality or hospitalization for these patients. Several clinical trials have recently started to try and bridge this major gap. There is an urgent need to focus on drug and device development for HFpEF as well as to understand HFpEF pathophysiology.

Keywords: HFpEF therapies, diastolic dysfunction

Introduction

Congestive heart failure (HF) is a growing epidemiologic problem and a major source of morbidity, mortality, and health care expenditure.1 Approximately 5.1 million people in the United States carry a diagnosis of HF, and the prevalence continues to rise. HF with reduced ejection fraction (HFrEF) and HF with preserved EF (HFpEF) each make up about one-half of the overall HF burden. Randomized clinical trials in patients with HF have mainly enrolled patients with HFrEF, and it is only in these patients that efficacious therapies have been demonstrated to date. Unlike with HFrEF, there have been no medical or surgical therapies shown to improve survival in patients with HFpEF. With its rising role in health care expenditure and increasing complexity of patients, there is a critical need for new drug and device therapies for HFpEF.

Epidemiology

The growth of the HF population is in part attributable to a changing demography, with HF being most prevalent in the elderly. In addition, the past 2 decades have also seen an increasing burden of common HF risk factors such as hypertension, diabetes, coronary artery disease, obesity, sleep apnea, and valvular heart disease. In addition, hospitalizations for HFpEF have also increased over time. These patients have a longer length of stay and are more likely to require skilled nursing care.1 Although mortality in HFpEF patients appears to be somewhat lower than the mortality in those with HFrEF in outpatient cohorts, observational studies now show a higher mortality in these patients than that seen in clinical trials.2,3

Pathophysiology

HFpEF is mostly related to the abnormal diastolic function of the left ventricle (LV) dysfunction and increase in arterial stiffness, which will lead to an abnormal
ventricular–arterial (V–A) coupling. In addition, these patients will have an abnormal LV systolic performance and chronotropic incompetence, which contribute to their abnormal exercise response (Figure 1).

Diastolic dysfunction

Diastolic dysfunction is the result of several comorbidities, including diabetes mellitus, hypertension, obesity, and chronic kidney disease, which induce a systemic inflammatory state with high circulating levels of interleukin-6 and tumor necrosis factor-α. This inflammatory state leads to coronary microvascular endothelial dysfunction with reduced vasodilator response to acetylcholine as a result of low nitric oxide (NO) bioavailability and increase in reactive oxygen species production. In addition, low NO bioavailability leads to decreased activity of protein kinase G and cyclic guanosine monophosphate (cGMP), which ultimately cause cardiomyocyte hypertrophy and fibrosis with increased stiffness and subsequent diastolic dysfunction. This cardiomyocyte stiffness has been related to an increase in the proportion of N2BA isoform of titin, a large protein that links the thick filaments of sarcomeres to the adjacent Z-disks, compared to its isoform N2B. This protein switching has been proposed as a myocardial mechanism to adjust for passive stiffness. However, in patients with HFpEF, the excess of protein kinase C and decrease in protein kinase G lead to a decrease in titin phosphorylation and thereby to an increase in the passive stiffness of titin.

Myocardial stiffness is not just related to cardiomyocyte stiffness but also to extracellular matrix changes, which in turn are determined by the amount of collagen and the extent of collagen cross-linking. In HFpEF, there is an increase in collagen type I, which results from an increase in its synthesis, depending on the activation of collagen-type-specific genes, and a decrease in its degradation secondary to a downregulation of matrix metalloproteinases. Finally, diastolic dysfunction will also be the result of an abnormal active process of relaxation related to an abnormal calcium handling mechanism, which causes an increase in resting calcium concentrations, mostly related to decreased expression of sarcoplasmatic reticulum calcium-ATPase and phospholamban as well as increased function of the sodium/potassium pump exchanger, which contributes to the increased intracellular calcium loading.

Arterial stiffness

Patients with HFpEF have impaired flow-mediated vasodilation and reduced aortic distensibility compared to healthy controls. This vascular dysfunction is related to endothelial dysfunction secondary to the decrease in NO bioavailability and can affect both proximal and distal arteries. This increase in stiffness and decrease in arterial compliance lead to an abnormal vasodilator response to exercise, which causes augmented pulse pressure waves and hemodynamic abnormalities that impair more the diastolic function of the LV and

---

Figure 1 Multiple factors that contribute to the pathophysiology of HFpEF.

Abbreviations: LV, left ventricular; ECM, extracellular matrix; HFpEF, Heart failure with preserved ejection fraction; CV, cardiovascular.
decrease peripheral-mediated vasodilation and, consequently, a decrease in blood flow to the skeletal muscle.\textsuperscript{14,15}

\section*{V–A coupling}

As mentioned earlier, the principal physiologic mechanism for HFpEF is an abnormal V–A coupling that results from LV and arterial stiffness (Figure 2). It refers to the interaction between the heart and the vascular system in order to provide the maximal working efficiency. In an optimal situation, V–A coupling allows the transfer of blood from the heart to the vascular system without excessive changes in blood pressure. It also provides an optimal cardiovascular (CV) reserve without affecting blood pressure with the minimum possible energy consumption.\textsuperscript{6,15} Normally, both the ventricular and arterial elastance are closely matched to get the optimal efficiency with a normal $E_v/E_a$ ratio of 0.5–1.0. In patients with HFpEF, the ventricular elastance ($E_v$) and arterial elastance ($E_a$) are elevated compared with normal individuals but the ratio is $\sim 0.5$, indicating that the system is already working at its maximal efficiency, compared with patients with HFrEF in whom the $E_v/E_a$ ratio is fivefold higher, indicating more afterload mismatch.\textsuperscript{16} This translates into systolic pressures that are more sensitive to changes in the LV end diastolic volume, and this small change in volume causes excessive changes in blood pressure. Also, small changes in ventricular elastance will cause large changes in blood pressure without significant change in stroke volume (SV), leading to an increase in myocardial oxygen consumption.\textsuperscript{15} These characteristics of the ventricular–vascular coupling lead to different results when vasodilators are administered to these patients. As demonstrated by Schwartztenberg et al, when nitroprusside was given to patients with HFpEF and HFrEF, although both groups showed similar reduction in blood pressure, patients with HFpEF had a greater drop in systolic blood pressure ($\sim 2.5$ fold) and mean arterial pressure ($\sim 1.5$ fold) compared to those with HFrEF. However, HFrEF patients had a threefold increase in SV and cardiac output (CO) while patients with HFpEF had a very small increase in SV, and almost 35\% of them had a decrease in SV. Therefore, except for patients with pulmonary edema and severe hypertension, the use of vasodilators could lead to increased risk of hypotension or drop in SV.

\section*{Chronotropic incompetence}

Patients with HFpEF elicit a chronotropic incompetence, which is related to decreased $\beta$-adrenergic stimulation during exercise due to increased baseline plasma catecholamines and autonomic dysfunction secondary to baroreflex sensitivity.\textsuperscript{17} In fact, patients with HFpEF had a 40\% less of an increase in heart rate and CO during exercise compared with matched controls, and their heart rate recovery after exercise was delayed. Thus, in these patients, exercising capacity correlated with the change in CO, heart rate, and vascular resistance but not end-diastolic volume.\textsuperscript{17}

\section*{Abnormal LV systolic function}

In hypertensive patients without HF, the myocardial contractility is increased, while in HFpEF patients the contractility is reduced. Increase in passive stiffness leads to decrease in contractility and abnormal systolic reserve, which has been associated with the inability to increase EF in response to exercise or beta-adrenergic stimulation and associated with an increase in mortality in these patients.\textsuperscript{18} These findings of abnormal systolic function were described by Yu et al,\textsuperscript{13} who found that patients with diastolic dysfunction have abnormal tissue Doppler indices suggestive of systolic dysfunction. More recently, it has been demonstrated that patients with HFpEF have significantly lower longitudinal strain and circumferential strain on tissue Doppler compared with normal controls and patients with hypertensive heart disease.\textsuperscript{20}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Effect of changes in arterial elastance ($E_a$) in SBP and SV.}
\textbf{Notes:} (A) Normal pressure–volume curve showing the relation between $E_v$ and $E_a$. (B) Pressure–volume curve in a patient with HFpEF showing a significant drop in SBP with mild increase in SV after decrease in $E_a$ (red line). (C) Pressure–volume curve in a patient with HFrEF with increase in SV and minimal change in SBP after decrease in $E_v$ with vasodilator therapy.
\textbf{Abbreviations:} SBP, systolic blood pressure; SV, stroke volume; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
\end{figure}
Right ventricle and pulmonary hypertension

Community-based studies have shown that 83% of patients with HFpEF have associated pulmonary hypertension. In these patients, the increase in pulmonary pressures is associated with passive increase in pulmonary vein pressure but also with increase in pulmonary artery resistance, which leads to "out of proportion" pulmonary hypertension. Also, it has been demonstrated that the increase in pulmonary wedge pressure seen in these patients has an impact on the compliance-resistance relation in the pulmonary vasculature. This leads to a bigger decline in compliance, causing significant changes in pulmonary arterial pulsatile load and, therefore, in right ventricular systolic load. The final result of these hemodynamic changes is right ventricular dysfunction, which leads to worse prognosis. In fact, one-third of patients with HFpEF had right ventricular dysfunction, which was related to higher right atrial volumes, greater ventricular dilatation, increase in diastolic stiffness, and higher mortality compared with patients without right ventricular dysfunction. It is also important to know that some of these patients with normal pulmonary wedge pressure at rest can have an increase in wedge pressure during exercise or after fluid bolus, which can lead to underdiagnosis of pulmonary hypertension related to left heart disease in such patients.

Diagnosis

The diagnosis of HFpEF is made in patients with signs or symptoms of HF, left ventricle ejection fraction (LVEF) >50%, and evidence of diastolic dysfunction. Echocardiography provides information regarding the LV function and diastolic dysfunction, but it also can give information regarding V–A coupling. An LVEF >50% obtained following the American Society of Echocardiography guidelines is considered normal or mildly abnormal and should be used as the cutoff value to define HFpEF. Cardiac myocytes produce pro-brain natriuretic peptide (BNP) in response to an increase of atrial or ventricular diastolic stretch, which is subsequently cleaved in the blood into N-terminal pro-brain natriuretic peptide (NT-proBNP) and BNP. In patients with HFpEF, NT-proBNP values correlate with diastolic relaxation indices including LV end-diastolic pressure and LV relation. In fact, progressively higher values were observed in patients with a mitral valve flow velocity pattern of impaired LV relaxation, pseudo-normalization, or restriction.

In terms of diastolic dysfunction, assessment of several echocardiographic measurements can help with the diagnosis. An E/E’ > 15 provides evidence of diastolic dysfunction (83% sensitivity and 92% specificity). On the other hand, a septal e’ ≥ 8, lateral e’ ≥ 10, and a left atrial (LA) volume < 34 mL/m² are compatible with a normal diastolic function. The European guidelines recommend making the diagnosis of HFpEF when E/E’ > 15 and excluding it when E/E’ < 8. When E/E’ is between 8 and 15, the addition of biomarkers such as elevated NT-pro BNP (>220 pg/mL) or BNP (>200 pg/mL) will help diagnose HFpEF. If the biomarkers are lower, then additional echocardiographic information, such as E/A < 0.5, deceleration time > 280 ms, or left atrial volume index > 40 mL/m² or LV myocardial infarction (MI) > 122 g/m² in women and > 149 g/m² in men, or the presence of atrial fibrillation can confirm the diagnosis.

Another imaging modality that can help with the diagnosis of HF, especially on those patients with difficult echocardiographic windows, is cardiac MRI. Cardiac MRI is the gold standard for evaluation of LV volume, LA volume, and LV mass measurements and provides several measurements similar to echocardiogram, including transmirtal and pulmonary vein flow, LA volume, strain, strain rate, and torsion.

Treatment

Current guidelines

Unlike the management of HFrEF, there is a paucity of large evidence-based trials demonstrating morbidity and mortality benefit for the treatment of HFpEF. Several ongoing trials with existing and novel agents are trying to fulfill this unmet need (Table 1). Current guidelines for the management of HFpEF recommend management of volume status with appropriate diuretic dosing; control of blood pressure; treatment of contributing risk factors such as sleep apnea, coronary artery disease, and valvular disease; and dietary education.

While all patients with HFpEF should be treated for underlying risk factors and comorbidities, hypertension is likely the most important to control. The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines support the use of beta-blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin receptor blocker (ARBs) for hypertension (IIa recommendation), and recommend ARBs be considered to decrease hospitalizations (IIb recommendation). The Heart Failure Society of America guidelines support ACE inhibitors or ARBs be considered in all patients with symptomatic atherosclerotic disease or diabetes and one additional risk factor. Beta-blockers are recommended for HFpEF patients with a history of myocardial infarction (MI), hypertension, or atrial fibrillation. The European Society of Cardiology guidelines have similar recommendations. These guidelines support the use of diuretics for symptom control. They also recognize the importance of...
appropriate treatment of comorbidities, such as hypertension, myocardial ischemia, and ventricular rate control in atrial fibrillation. The guidelines also note that calcium channel blockers can be considered in patients with HFpEF for the treatment of the comorbidities listed earlier. However, in patients with HFrEF, these agents are contraindicated.

ACE inhibitors
The data on the use of ACE inhibitors for HFpEF are less clear than the information regarding its role in HFrEF.

Angiotensin II promotes ventricular hypertrophy and fibrosis, both of which are contributors to HFpEF, as well as vasoconstriction and vascular remodeling. By blocking the formation of angiotensin II, ACE inhibitors are a potential target for HFpEF treatment.

The Perindopril in Elderly People with Chronic Heart Failure study is the largest trial to date examining the use of ACE inhibitors in HFpEF. This double-blind, multicenter, placebo-controlled, randomized trial compared perindopril 4 mg daily to placebo in 850 elderly patients with HFpEF with CV hospitalization and isoproterenol

dexmedetomidine

Abbreviations: CV, cardiovascular; HF, heart failure; NT-proBNP, N-terminal pro-brain natriuretic peptide; IL, interleukin; VO₂, aerobic exercise capacity; HFpEF, heart failure with preserved ejection fraction; VE/VCO₂, ventilation efficiency/carbon dioxide ratio.

Table 1 Ongoing clinical trials in patients with HFpEF

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Clinical trial identifier</th>
<th>Estimated enrollment, phase</th>
<th>Objective</th>
<th>Primary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCZ696 (neprilysin inhibitor)</td>
<td>NCT01920711</td>
<td>n=4300 Phase III</td>
<td>To evaluate the effect of LCZ696 compared to valsartan in the reduction of CV death and HF hospitalizations</td>
<td>Cumulative number of primary composite events of CV death and total (first and recurrent) HF hospitalizations</td>
</tr>
<tr>
<td>Verapamil (soluble guanylate cyclase stimulator)</td>
<td>NCT01951638</td>
<td>n=477 Phase II</td>
<td>To find the optimal dose of once daily oral soluble guanylate cyclase stimulator</td>
<td>Change of log-transformed NT-proBNP and left atrial volume</td>
</tr>
<tr>
<td>Anakinra (IL-1 receptor antagonist)</td>
<td>NCT02173548</td>
<td>n=60 Phase II</td>
<td>To determine effects on CV function of anti-inflammatory IL-1 blockade</td>
<td>Absolute changes in aerobic exercise capacity (peak VO₂) after 12 weeks and absolute changes in VE/VCO₂ after 12 weeks treatment</td>
</tr>
<tr>
<td>Udenafil (phosphodiesterase 5 inhibitor)</td>
<td>NCT01599117</td>
<td>n=52 Phase III</td>
<td>To determine if udenafil will improve symptoms, exercise capacity, and hemodynamic status in HFpEF</td>
<td>Change of maximal VO₂ in cardiopulmonary exercise test</td>
</tr>
<tr>
<td>Furosemide ± dopamine</td>
<td>NCT01901809</td>
<td>n=120 Phase IV</td>
<td>To test the hypothesis that changing the method of diuresis (continuous vs bolus) with or without low-dose dopamine will reduce renal injury</td>
<td>Change in glomerular filtration rate at 72 hours</td>
</tr>
<tr>
<td>Isosorbide dinitrate ± hydralazine</td>
<td>NCT01516346</td>
<td>n=54 Phase II</td>
<td>To test effect of prolonged isosorbide dinitrate ± hydralazine therapy (24 weeks) on arterial wave reflections</td>
<td>Change in late systolic load from wave reflections between baseline and after 24 weeks of randomized therapy</td>
</tr>
<tr>
<td>Inorganic nitrate</td>
<td>NCT02256345</td>
<td>n=12 Phase II</td>
<td>To determine the safety, tolerability, and dose–response to inorganic nitrate on exercise capacity in HFpEF</td>
<td>Change in peak VO₂ from baseline to the end of 1 week of administration for each dose</td>
</tr>
<tr>
<td>Inhaled sodium nitrite</td>
<td>NCT02262078</td>
<td>n=30 Phase II</td>
<td>To assess the effects of nebulized inhaled nitrite administration on resting and exercise hemodynamics</td>
<td>Exercise pulmonary capillary wedge pressure</td>
</tr>
<tr>
<td>Ranolazine</td>
<td>NCT01505179</td>
<td>n=40 Phase IV</td>
<td>To determine whether treatment with ranolazine will improve exercise capacity</td>
<td>Change in exercise capacity from baseline at 6 weeks</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>NCT01157481</td>
<td>n=226 Phase IV</td>
<td>To determine if nifedipine can improve HF clinical response</td>
<td>HF clinical composite response endpoint</td>
</tr>
<tr>
<td>Nebivolol</td>
<td>NCT02053246</td>
<td>n=40 Phase II</td>
<td>To determine if nebivolol will improve disease severity in patients with pulmonary hypertension associated with HFpEF</td>
<td>Changes in pulmonary vascular pressure</td>
</tr>
<tr>
<td>Carvedilol vs nebivolol</td>
<td>NCT02619526</td>
<td>n=62 Phase IV</td>
<td>To compare the relative effectiveness of carvedilol and nebivolol in treating HF in aged patients with preserved EF</td>
<td>Ratio of transmural E velocity to early diastolic mitral annular velocity (E/E)</td>
</tr>
<tr>
<td>Static handgrip, dexametomidine, glycopyrrolate, isoproterenol</td>
<td>NCT02524114</td>
<td>n=45 Phase II</td>
<td>To determine the mechanisms of chronotropic incompetence in patients with HFpEF</td>
<td>Cardiac beta-receptor sensitivity</td>
</tr>
</tbody>
</table>
within 6 months. The primary outcome was a composite of all-cause mortality and HF hospitalization. The study failed to meet sufficient power for its primary endpoint due to lower than expected enrollment and event rates and open-label ACE inhibitor use at 1 year. In the first year of follow-up, 15.3% of placebo patients and 10.8% of perindopril patients experienced a primary endpoint (HR 0.69; 95% CI 0.47–1.01; P=0.055). In addition 12.4% of placebo patients and 8% perindopril patients experienced HF hospitalizations (HR 0.63; 95% CI 0.41–0.97; P=0.033) at 1 year, but this was not significant for the entire study duration. The perindopril group also demonstrated significant improvements in functional class and 6-minute walk distance (6MWD) compared to placebo at 1 year. Unfortunately, the People with Chronic Heart Failure trial did not provide definitive evidence on morbidity and mortality outcomes for the use of ACE inhibitors in the HFpEF population.

Other smaller trials have demonstrated conflicting results for significant clinical benefits of ACE inhibitors. In a small study of 74 elderly patients with HFpEF, quinapril use failed to demonstrate improvement in exercise tolerance, quality of life, worsening HF, or hospitalizations. In another small study of 21 elderly patients with HF with prior MI and normal EF, enalapril demonstrated improvement in New York Heart Association (NYHA) functional class, exercise duration, reduction of cardiothoracic ratio, and left ventricular mass compared to placebo.

Angiotensin receptor blockers

ARBs, like ACE inhibitors, help blunt the adverse CV effects of angiotensin II. However, ARBs exert their effect further downstream and block the association of angiotensin II with its receptor AT1. Two large, randomized, double-blind, placebo-controlled trials have evaluated morbidity and mortality outcomes with ARB use in the HFpEF population. The Candesartan in Heart Failure Reduction in Mortality (CHARM)-Preserved trial randomized 3,023 patients with HF with NYHA function class II–IV, LVEF >40%, and history of cardiac hospitalization to receive candesartan (target dose 32 mg once daily) or placebo. The primary outcome was CV death or HF hospitalization. The primary endpoint was met in 22% of candesartan patients and 24% of placebo patients (unadjusted HR 0.89; 95% CI 0.77–1.03; P=0.118; adjusted HR 0.86; 95% CI 0.74–1.0; P=0.051). Fewer patients were admitted for one HF hospitalization (P=0.017) and there were less total number of HF admissions (P=0.014) in the candesartan group compared to placebo. The CHARM-Preserved trial was the first to demonstrate a moderate benefit for HF hospitalizations in the use of ARBs in the HFpEF population.

The I-PRESERVE trial followed the CHARM-Preserved trial but failed to support the potential improvement in clinical outcomes that CHARM-Preserved demonstrated. This trial enrolled 4,128 patients aged 60 years or above with HF, LVEF at least 45%, NYHA class II–IV symptoms with an HF hospitalization 6 months prior to enrollment, or ongoing NYHA class III or IV symptoms without hospitalization. Patients were randomized to receive irbesartan (target dose 300 mg daily) or placebo. The primary outcome was a composite of all-cause death or CV hospitalization. The primary outcome occurred in 36% of irbesartan patients and 37% of placebo patients (HR 0.95; 95% CI 0.86–1.05; P=0.35). There was no significant difference in secondary endpoints including death, CV hospitalization, or worsening HF. The authors speculated that several factors might have contributed to the negative study results, including high rate of discontinuation and frequent use of other renin–angiotensin–aldosterone system agents including ACE inhibitors (in ~40% patients).

Two other small trials have examined ARB use in patients with HFpEF. Both studies examined the effects of an ARB (losartan or valsartan) on exercise tolerance in patients with HFpEF and demonstrated conflicting results compared to placebo.

Aldosterone antagonists

Aldosterone can promote interstitial collagen deposition and fibrosis, leading to ventricular stiffness. It is this mechanism that makes aldosterone antagonism an attractive strategy for the treatment of HFpEF. Several small studies looking at aldosterone antagonists in HFpEF showed improved E/A ratio, decreased deceleration time, and decreased LV wall thickness.

The Aldo-DHF trial was a randomized, double-blind, placebo-controlled trial designed to assess the effect of spironolactone's ability to improve diastolic dysfunction and maximal exercise capacity in HFpEF. The trial included 422 ambulatory patients with NYHA II or III symptoms, LVEF >50%, diastolic dysfunction or atrial fibrillation at presentation, and peak VO₂ of ≤25 mL/kg/min. Patients who received spironolactone 25 mg daily showed improved diastolic dysfunction (E/E' decreased from 12.7 to 12.1 in spironolactone and increased from 12.8 to 13.6 in placebo over 12 months, P<0.001 for difference between groups) but no improvement in exercise capacity, patient symptoms, or quality of life.

The TOPCAT trial was a randomized, double-blind trial in which spironolactone was compared to placebo in 1,722 patients with HFpEF (EF ≥45%). All patients were required...
to be ≥50 years of age and have recent hospitalization within 12 months prior to enrollment. A majority of enrolled patients had NYHA II symptoms, and the mean dose of spironolactone was 25 mg/d. There was no difference with spironolactone versus placebo in the primary composite endpoint of death from CV causes, aborted cardiac arrest, or hospitalization for HF (18.6% spironolactone vs 20.4% placebo, HR 0.89; 95% CI 0.77–1.04; P=0.14). When components of the primary outcome were evaluated individually, hospitalization for HF was significantly reduced with spironolactone versus placebo (12% vs 14.2%, HR 0.83; 95% CI 0.69–0.99; P=0.04). While the overall results of the TOPCAT trial were negative, there may be a role for spironolactone to reduce HF hospitalizations in HFrEF.

Nephrilysin inhibitors

Nephrilysin is an endopeptidase that degrades vasoactive peptides such as natriuretic peptides. Its inhibition blocks the degradation of vasoactive peptides. LCZ696, an angiotensin receptor nephrilysin inhibitor, consists of a nephrilysin inhibitor and valsartan in one compound and was studied in HFrEF within the PARAMOUNT trial. This was a Phase II, randomized, parallel group, double-blind, multicenter trial, comparing LCZ696, a nephrilysin inhibitor (n=134), to valsartan (n=132) in patients with HFrEF (EF ≥45%). LCZ696 was titrated to 200 mg twice daily and valsartan to 160 mg twice daily, which was achieved in 81% and 79% of patients, respectively. LCZ696 showed reduction of primary endpoint, change in NT-pro BNP from baseline to 12 weeks versus placebo (783–605 pg/mL LCZ696 vs 862–835 pg/mL placebo, P=0.005). The authors also noted improvement in LA remodeling and improvement in NYHA functional class at 36 weeks. However, hypothesis-generating larger scale trials should be completed before a role in HFrEF is determined. Sacubatril/valsartan (Entresto™) is an angiotensin receptor nephrilysin inhibitor that is currently approved by the US FDA to reduce the risk of CV death and hospitalization for HF in patients with HFrEF (NYHA Class II–IV) but has no approved indication for HFrEF at this time.

Beta-blockers

The first trial to assess beta-blocker use in HFrEF evaluated the use of propranolol in a small (n=158) study in patients with HFrEF (EF ≥40%, mean EF 56%). Propranolol 30 mg three times daily showed a reduction in total mortality when compared to no propranolol (56% vs 76%, P=0.007) and a reduction in total mortality combined with nonfatal MI (59% vs 65%, P=0.002). However, despite the reduction in total mortality, there was no significant difference in the cardiac deaths between groups. The SENIORS trial was a placebo-controlled trial comparing nebivolol’s effect on the composite of all-cause mortality or hospitalization for CV causes and included both HFrEF and HFrEF patients. A subanalysis of this trial compared patients with HFrEF (EF ≥35%) versus HFrEF (<35%). The composite of all-cause mortality or hospitalization for CV causes was not significantly different between patients with HFrEF (31.2%) and those with HFrEF (34.2%), (HR 0.86; 95% CI 0.72–1.04 vs HR 0.81; 95% CI 0.63–1.04, P=0.720). As this is a subanalysis, it is still not completely evident whether beta-blockers have the same evidence in HFrEF as in HFrEF.

Contrary to the mortality results of the 1997 propranolol study, the Japanese Diastolic Heart Failure Study included 245 patients with LVEF >40%, randomized to either carvedilol or placebo. After a follow-up of 3.2 years, there was no significant difference in the composite of CV death and unplanned hospitalization for HF (24.2% vs 27.2%, HR 0.902 [95% CI 0.543–1.486], P=0.6854). A retrospective analysis of the OPTIMIZE-HF registry looked at a larger population than the previous studies to compare the use of beta-blockers on the composite endpoint of all-cause mortality or HF rehospitalization in 1,099 pairs of HFrEF propensity-matched patients (EF ≥40%, mean 55%). During 6 years of follow-up, the beta-blocker group had no significant association with the composite endpoint of all-cause mortality or HF rehospitalization versus the no beta-blocker group (HR 1.01; 95% CI 0.94–1.13, P=0.569).

Use of beta-blockers has been suggested to improve LVEF and NYHA symptoms and exercise capacity and improve E/A ratio, but these results have not been consistently noted in large randomized, controlled trials. The Effects of Long-term Administration of Nebivolol and the clinical symptoms, exercise capacity, and left ventricular function of patients with Diastolic Dysfunction (ELANND) trial goes against the idea that beta-blocker use might improve exercise capacity. ELANND was a multicenter, double-blind, placebo-controlled, randomized, parallel group trial of 116 patients randomized to nebivolol versus placebo in patients with HFrEF (LVEF >45%). Nebivolol showed no difference in the primary endpoint of change in 6MWD from baseline or peak oxygen uptake.

While improving diastolic filling time is one of the theories for the use of beta-blockers in HFrEF, it is unclear whether patients with higher heart rate have increased benefit with beta-blockers. The SWEDIC trial included 113 patients with HFrEF who were randomized to carvedilol 25 mg twice daily
(50 mg bid for patients >85 kg) versus placebo for 6 months. Sildenafil significantly increased age-adjusted E/A ratio from baseline to 6 months versus placebo (0.72–0.83 carvedilol vs 0.71–0.76 placebo, P=0.046). Interestingly, the data were also analyzed by baseline heart rate. Patients with a heart rate <71 bpm did not have a significant increase in the E/A ratio, while patients with a heart rate >71 bpm did have a significant increase in the E/A ratio. This study did not meet its intended power, so its results should be interpreted with caution.

**Calcium channel blockers**

The ACCF/AHA HF guidelines caution that non-dihydropyridine calcium channel blockers can be harmful in patients with HFrEF due to their negative inotropic effect. However, in patients with HFpEF where diastolic and not systolic dysfunction is the primary concern, the same logic may not be applicable. While limited by their size, a few trials have been conducted analyzing calcium channel blocker use in HFpEF.

In a 5-week placebo-controlled, crossover trial of 20 men with HFpEF (EF >45%) were assigned to verapamil or placebo. All patients were required to have HF symptoms for more than 3 months. Verapamil was titrated as tolerated to 120 mg three times daily. Verapamil showed improvement in baseline HF score (median improvement 3 vs 1, P<0.01), improvement in treadmill exercise capacity from baseline (+13.9±4.3 vs +10.7±3.4 minute, P<0.05, n=12), and improvement in LV peak filling rate from baseline (2.29±0.54 vs 1.85±0.45 end diastolic volume/second). This study is difficult to extrapolate to a general HFpEF population given its small sample size and entirely male population.

As is the case with non-dihydropyridine calcium channel blockers, data for dihydropyridine calcium channel blockers is also limited. An analysis of the ALLHAT trial compared amlodipine, chlorthalidone, lisinopril, and doxazosin for the treatment of hypertension with regard to the occurrence of hospitalized HFpEF or HFrEF. There were 404 patients with HFpEF (EF ≥50%). Chlorthalidone reduced the risk of HFpEF compared to amlodipine, lisinopril, or doxazosin (HR: 0.69 [95% CI 0.53–0.91; P<0.009], 0.74 [95% CI 0.56–0.97; P<0.032], and 0.53 [95% CI 0.38–0.73; P<0.001], respectively).

**Sildenafil**

Sildenafil is an inhibitor of phosphodiesterase-5 (PDE-5); this enzyme degrades cGMP. Increased availability of cGMP may provide benefits for both vascular and myocardial remodeling, including attenuating hypertrophy, fibrosis, and impaired cardiac relaxation. The RELAX trial was a multicenter, double-blind, placebo-controlled randomized trial examining the use of PDE-5 inhibition in HFpEF. The study randomized 216 HF patients with EF ≥50% and reduced exercise capacity to receive sildenafil (20 mg three times daily titrated to 60 mg three times daily) or placebo. The primary outcome was change in peak oxygen consumption after 24 weeks of therapy. At the end of follow-up, median change in peak oxygen consumption (–0.20 mL/kg/min [IQR −1.70 to 1.11] for sildenafil versus 0.20 mL/kg/min [IQR −0.70 to 1.00] for placebo; P=0.90), change in 6MWD (5.0 m for sildenafil vs 15.0 m for placebo; P=0.92), or clinical rank score (94.2 for sildenafil vs 95.8 for placebo; P=0.85) between placebo and sildenafil did not differ significantly.

Although the RELAX trial did not show significant improvement in exercise capacity, an earlier trial examined the use of sildenafil in patients with HFpEF on hemodynamic outcomes. Forty-four patients with HFpEF and pulmonary artery systolic pressure >40 mmHg were randomized to receive sildenafil 50 mg three times daily or placebo. At 6 months and 12 months, the sildenafil group demonstrated improvements in right heart and pulmonary hemodynamic endpoints, including mean pulmonary artery pressure (PAP), as well as quality-of-life scores. Another small, single-center trial examined the use of sildenafil titrated to 60 mg three times daily or placebo in 52 patients with pulmonary hypertension due to HFpEF. There was no significant difference in mean PAP at 12 weeks, as well as other hemodynamic parameters included pulmonary arterial wedge pressure (PAWP), CO, and peak VO₂.

**Riociguat**

Riociguat is a soluble guanylate cyclase (sGC) stimulator that targets the NO-soluble guanylate cyclase–cyclic guanosine monophosphate (NO-sGC–cGMP) signaling pathway. However, its mechanism is unique compared to that of the PDE-5 inhibitors. Riociguat directly stimulates sGC independent of endogenous NO, but also sensitizes sGC to endogenous NO as well. The DILATE-1 trial examined the use of riociguat in patients with HFpEF and pulmonary hypertension. Thirty-six HF patients with LVEF >50%, mean PAP ≥25 mmHg, and PAWP >15 mmHg were randomized to receive one dose of placebo or riociguat at 0.5 mg, 1 mg, or 2 mg. The primary outcome was peak decrease in mean PAP up to 6 hours after administration. While there was no significant change in the primary outcome (P=0.6), riociguat 2 mg significantly increased SV and cardiac index and decreased systolic blood pressure and right ventricular end-diastolic area.
However, generalizing the results from a single-dose trial should be done with caution. There is an ongoing trial examining the use of another oral guanylate cyclase stimulator, vericiguat, in patients with HFpEF. The primary outcomes include change in NT-proBNP and LA volume compared to placebo (BAY1021189).

Nitrates

The NEAT-HFpEF trial was a recent multicenter, randomized, placebo-controlled trial that examined the ability of isosorbide mononitrate to improve activity tolerance in patients with HFpEF. In this crossover study, 110 patients were randomized to receive isosorbide mononitrate titrated to 120 mg daily or placebo over 6 weeks, with crossover for another 6 weeks. The primary endpoint was daily activity level, as defined by average daily accelerometer units. The isosorbide group demonstrated a nonsignificant decrease in daily activity and hours of activity per day compared to placebo. There was also no significant difference in 6MWD, quality-of-life scores, or NT-proBNP levels compared to placebo.

Two small studies (<30 patients each) explored the use of inorganic nitrite and nitrate as an alternative source of bioactive NO over traditional organic nitrates for patients with HFpEF. Both studies demonstrated improvement in hemodynamic measures and exercise capacity with treatment. However, these small studies should be considered hypothesis-generating and not generalized to a larger population with long-term therapy.

Digoxin

The Digitalis Investigation Group (DIG) dataset looked specifically at the HFpEF population (EF 45%) to compare digoxin (n=496) versus placebo (n=492) and found no difference in the combination of HF hospitalization or mortality, the combination of HF hospitalization or CV mortality, or mortality alone after a mean duration of 37 months. Given that there was a difference in hospitalization for HFpEF in the original trial, but not for HFpEF in the above-mentioned trial, a propensity-match population of 916 pairs of patients with HFpEF and HFpEF were analyzed. The combined endpoint of HF hospitalization or mortality was similar in patients with HFpEF (HR 0.85; 95% CI 0.67–1.08, P=0.188) and those with HFpEF (HR 0.79; 95% CI 0.60–1.03, P=0.085) with no significant interaction between digoxin and LVEF. The effect of digoxin on HF hospitalization was also similar between HFpEF (HR 0.80; 95% CI 0.62–1.03, P=0.79) and HFpEF (HR 0.77; 95% CI 0.57–1.03, P=0.074) irrespective of LVEF. However, after 2 years of follow-up digoxin, there was a significant benefit of digoxin on the combined endpoint of HF hospitalization or mortality. The authors suggest that the lack of benefit seen in the HFpEF subset of the initial trial was due to the sample size.

Ranolazine

The Ranolazine for the Treatment of Diastolic Heart Failure (RALI-DHF) trial was a small, prospective, single-center, randomized, double-blind, placebo-controlled, proof-of-concept study evaluating the effect of ranolazine in 20 patients with HFpEF (LVEF ≥45%). The intent of this trial was to determine whether ranolazine improved diastolic function in HFpEF patients. Patients received an IV bolus followed by continuous infusion of ranolazine or placebo for 24 hours and then transitioned to ranolazine 1,000 mg twice daily or placebo. Ranolazine showed improvement in some measures of hemodynamics but no improvement in relaxation parameters. Larger studies are required before ranolazine could be recommended for the treatment of HFpEF.

Ivabradine

Ivabradine was approved by FDA in 2015 for the treatment of HFrEF to reduce hospitalizations for stable, symptomatic patients with heart rate >70 bpm on maximally tolerated beta-blockers. The role of ivabradine in HFpEF has not been established. The theory that patients with HFpEF may have detrimental effects from high heart rate during exercise due to reduced time for diastolic filling led to an analysis of ivabradine in HFpEF. Sixty-one patients with HFpEF (EF ≥50%) were analyzed in a prospective, blinded, parallel-group, placebo-controlled trial to evaluate ivabradine’s effect on exercise tolerance and LV function. Patients received either ivabradine 5 mg twice daily or placebo for 7 days. Ivabradine improved exercise capacity from baseline (4.2±1.8 vs 5.7±1.9 metabolic equivalent [METs], P=0.001) and peak oxygen uptake (14.0±6.2 mL/min/kg vs 17.0±3.3 mL/min/kg, P=0.001), with reduction in exercise-induced increase in the ratio of peak early diastolic mitral flow velocity (3.1±2.7 vs 1.3±2.0, P=0.004). The drug showed improved exercise capacity from baseline compared to patients in the control group (1.5±1.2 vs 0.4±1.2 METs, P=0.001) and also improved peak oxygen uptake (3.0±3.6 mL/kg/min vs 0.4±2.7 mL/kg/min, P=0.003).

The utility of heart rate reduction with ivabradine in HFpEF patients has been questioned in a prospective, double-blind, randomized, crossover study. This study compared ivabradine 7.5 mg twice daily versus placebo in 22 symptomatic HFpEF patients (LVEF ≥50%) over 2 weeks, and the result was then compared with a paralleled study
in 22 asymptomatic hypertensive volunteers. All HFpEF patients had objective evidence of exercise limitation (peak VO₂ <80%). Ivabradine worsened the primary endpoint of change in peak VO₂ in the HFpEF cohort (−2.1 mL/kg-min vs 0.9 mL/kg-min, P=0.003). There were no significant differences in secondary endpoints including tissue-Doppler-derived E/E’ at echocardiography, plasma brain natriuretic peptide, and quality-of-life scores. Ivabradine did significantly reduce peak heart rate in response to exercise in the HFpEF (107 bpm vs 129 bpm; P<0.0001) and hypertensive cohorts (127 bpm vs 145 bpm; P=0.003).

The results of this study are in contrast to those seen in the earlier aforementioned study. The authors postulate that the latter study, having an older population (75 years vs 67 years), may represent a group more sensitive to heart rate reduction. The two studies also differ in ivabradine dose and duration of therapy. Larger trials using ivabradine for extended duration need to be conducted to determine a role in HFpEF.

**Statins**

While there are several studies published on the potential role of statins in HFpEF, there are no randomized trials to support its use in routine clinical practice. The first trial to evaluate the effect of statin therapy in HFpEF included 137 patients with EF ≥50%. Patients treated with statins (n=68) were compared to non-statin-treated patients (n=69). Treatment with statins was associated with an improvement in survival (relative ratio 0.22, 95% CI 0.07–0.64, P=0.006). However, the study was not powered to detect a difference in mortality, and there were a low number of total events (only 20 deaths during the study period). Authors of this study caution that the benefits of statin therapy might reflect other unmeasured factors related to improved survival.

In an observational study of 13,533 Medicare patients with HFpEF (EF >50%), discharged on statin therapy was associated with improved 1- and 3-year mortality (relative ratio 0.69, 95% CI 0.61–0.78; relative ratio 0.73 and 95% CI 0.68–0.79, respectively). Improved mortality was reported to be independent of age, lipid levels, and comorbidities including coronary artery disease, diabetes, and hypertension. Given the observational nature of this study, the results should be interpreted with caution. In an analysis to determine whether statins are associated with improved outcomes after discharge from hospitalization for HF, 5,171 patients were stratified into four subgroups: patients with and without coronary artery disease, HFpEF (n=706), and HFpEF. Statins were shown to be associated with improved outcomes for HF patients in the overall study population. However, in contrast to the previously mentioned studies, HFpEF patients had no difference in 5-year mortality in patients receiving statins versus those who were not (49% vs 55%, P=0.20). There was also no difference in the primary composite outcome of death from any cause, nonfatal MI, or nonfatal stroke (HR 0.92, 95% CI 0.82–1.02, P=0.12).

In a recent prospective study of HFpEF patients (EF ≥50%), statin use was evaluated in a matched population of 2,074 statin users and 2,074 non-statin users. Statin use was associated with a higher rate of 1-year survival compared with those who were not treated (85.1% vs 80.9%, HR 0.80; 95% CI 0.72–0.98, P<0.01). The statin group reduced CV death (HF 0.86; 95% CI 0.75–0.98; P=0.026) and reduced composite all-cause mortality (HR 0.89; 95% CI 0.82–0.96; P=0.003).

While the ACCF/AHA HF guidelines support the use of statin therapy for patients with known atherosclerotic disease, statins are not currently recommended for the treatment of HF alone in the absence of other indications for their use.

**Device therapy**

Given that rises in LA pressure and pulmonary venous congestion are shown to herald an HF decompensation in patients with HFpEF and that the current mainstay of management includes volume management with diuretics, a patient management strategy utilizing ongoing direct or indirect measurements of LV filling pressures holds promise. The REDUCE LAP-HF trial (NCT0191361) with the objective to evaluate the safety and performance of the inter-atrial septal defect system in the treatment of HF patients with elevated left atrial pressure who remain symptomatic despite appropriate medical management just finished patient enrollment.

The CARDIOMEMS device is a wireless, implanted pulmonary artery pressure monitor implanted in the distal pulmonary artery during a right heart catheterization procedure. Patients transmit hemodynamic data daily using a wireless RF transmitter. In the CHAMPION trial, which was a single-blind clinical trial of the CARDIOMEMS device in patients with NYHA functional class III HF of any etiology, a management strategy using the hemodynamic data showed a significant reduction in HF hospitalizations. The CARDIOMEMS system has subsequently been approved in Europe and the United States.

**Conclusion**

HFpEF prevalence is increasing, and these patients face impaired health status while imposing a significant economic burden. To date, there is no approved therapy for these patients.
There is an urgent need to focus on drug and device development for HFpEF. This would include characterizing HFpEF further to understand better clinical manifestations, contribution of comorbidities, and mechanisms. Developing longitudinal registries focused on collecting clinical, imaging, laboratory, treatment patterns, and outcomes data may facilitate this.

Disclosure
The authors report no conflicts of interest in this work.

References
33. McMurray JJ, Adamopoulos S, Anker SD, et al; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2012;14(4):303–360.


